Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy.

ABSTRACT: Fatigue is a common and often debilitating adverse event among patients receiving immune checkpoint inhibitor (ICI) therapy, yet its underlying immunologic mechanisms remain poorly defined. We prospectively collected clinical data and blood samples from patients with solid tumors receiving ICI therapy. Patients were prospectively surveyed at month 2, 4, or 6 on treatment to assess for the presence and severity of fatigue as compared with treatment baseline. We analyzed peripheral lymphocyte populations by cytometry by time of flight and peripheral levels of 39 cytokines with a Luminex multiplex assay to identify dynamic immune changes associated with ICI-related fatigue. Of 53 patients enrolled, 31 (58.5%) reported worsening fatigue during ICI therapy. Patients reporting fatigue exhibited

SUBMITTER: Li HL 

PROVIDER: S-EPMC12485599 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature